Hestia Duran I Reynals

Verified siteinfo

Spain Avinguda de la Granvia de l'hospitalet 199-203, 08908 L'hospitalet De Llobregat, Spain

8 trials recruiting
Breast cancer · Colorectal cancer metastatic · Plasma cell myeloma
Adult patients

About Specializations

Hestia Duran I Reynals in L'hospitalet De Llobregat, Spain specialises in clinical trials of conditions such as Breast cancer, Colorectal cancer metastatic, Plasma cell myeloma, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiology and Rare Diseases

The medical center is at the forefront of research in cardiology and rare diseases, with a particular focus on light Chain (AL) Amyloidosis. This condition is characterized by the deposition of amyloid proteins in organs and tissues, leading to organ dysfunction.

Light Chain (AL) Amyloidosis
Advanced Heart Failure
Cardiac Amyloidosis

Through its innovative research, the center is contributing to the development of new therapeutic strategies aimed at improving patient outcomes and quality of life. The ongoing studies are pivotal in understanding the pathophysiology of amyloidosis and enhancing the efficacy of treatment protocols.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Avinguda de la Granvia de l'hospitalet 199-20308908 L'hospitalet De LlobregatSpain

Open in maps ↗

Recruiting now: 8 trials
Conditions studied: 22
Partner status: Verified site

More sites in L'hospitalet De Llobregat Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

20 clinical trials

Colorectal cancer metastatic

Recruiting

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Lung neoplasm malignant+2

Recruiting

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Hepatocellular carcinoma

Recruiting

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

Registered drugNo placebo

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Fundacion Geltamo

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Zanubrutinib and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Registered drugNo placebo

Study on Zanubrutinib and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Fundacion PETHEMA

Contact Research Centre

Metastatic renal cell carcinoma

Recruiting

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Consorzio Oncotech

Contact Research Centre

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Institut Gustave Roussy

Contact Research Centre

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana